Filana Therapeutics FLNA 深 沪
已收盘 11-13 16:00:00 美东时间
0.4251
-0.023
-5.11%
华盛通- 最 高0.4702
- 今 开0.46
- 成交量 31.99万股
- 最 低 0.4225
- 昨 收 0.448
- 总市值 2.14万
- 52周最高 3.45
- 市盈率 静 --
- 换手率 636.01%
- 52周最低 0.4225
- 委 比 -2.30%
- 总股本 5.03万
- 历史最高 146.16
- 量 比 0.79
- 振 幅 10.65%
- 历史最低 0.4225
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Filana Therapeutics announced the appointment of Jill M. Quigley to its Board of Directors. With over 20 years of experience in biotechnology, Quigley will contribute to the company's clinical development of simufilam for TSC-related epilepsy. The company plans to initiate a Phase 2a trial in early 2027.
11-11 13:00
Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate
Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
11-05 21:26
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
Filana Therapeutics reported third-quarter 2026 financial results, highlighting the lifting of the FDA clinical hold on simufilam for TSC-related epilepsy and plans to begin patient screening in the Phase 2a study by Q1 2027. Recent research in *Cells* provides new insights into simufilam's mechanism of action. The company ended Q3 with $47 million in cash, a 2% decrease in R&D expenses, and a 6% decrease in G&A expenses. Net loss was $10.7 milli...
11-05 13:00
Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the publication by Yale researchers of new preclinical research on...
10-28 20:06
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
New research on simufilam, a drug being developed by Filana Therapeutics for TSC-related epilepsy, shows it reduces ATF4 expression by 37% and improves mitochondrial function without significantly affecting mTORC1 signaling. These findings, published in *Cells*, support its potential as a novel treatment approach. Filana expects to begin patient screening for its planned Phase 2a study by early 2027.
10-28 12:00
Appeals Court Vacates Class Certification in Filana Case
Filana Therapeutics ( ($FLNA) ) has provided an announcement. On October 16, 20...
10-20 20:38
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company developing therapies for TSC-related epilepsy, announced that its management team will participate in the 2026 Maxim Growth Summit on October 12-14, 2026, at The Hard Rock Hotel NYC. The event will feature one-on-one meetings. Filana focuses on modulating the filamin A protein to treat central nervous system disorders. For more information, visit www.maximgrp.com/2026-growth-summit...
10-09 12:00
Filana Therapeutics shares are trading higher after a Form 4 filing showed its President & CEO bought 306,813 shares at an average price of $0.91 each.
Filana Therapeutics shares are trading higher after a Form 4 filing showed its President & CEO bought 306,813 shares at an average price of $0.91 each.
10-01 22:25
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the cl...
09-22 20:06
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Filana Therapeutics has lifted the clinical hold on its IND application for simufilam to treat TSC-related epilepsy, enabling the initiation of a Phase 2a study in patients aged 12 to 55. Patient screening is expected to begin in Q1 2027. The company has prepared for the trial by engaging a clinical research organization, identifying trial sites, and recruiting investigators. Collaboration with the TSC Alliance aims to support patient engagement....
09-22 12:00
